Dupilumab significantly improves sleep quality and other signs and symptoms in atopic dermatitis patients Dr. Shravani Dali28 Aug 2023 10:00 AM ISTDupilumab significantly improves sleep quality and other signs and symptoms in atopic dermatitis patients suggests a new study published in the...
Dupilumab improves clinical outcomes in patients having chronic rhinosinusitis with nasal polyps Dr. Kamal Kant Kohli26 July 2023 9:30 AM ISTUSA: A recent study published in Allergy & Asthma Proceedings on the efficacy of the human monoclonal antibody Dupilumab in patients with chronic...
Sanofi Dupixent gets nod in India for treatment of adults with moderate-to-severe atopic dermatitis Ruchika Sharma11 July 2023 1:12 PM ISTDupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement.
Dupilumab lessens disease severity in COPD patients with type 2 inflammation Dr. Kamal Kant Kohli28 Jun 2023 8:00 PM ISTChronic obstructive pulmonary disease patients with type 2 inflammation saw rapid and sustained improvements in their disease after treatment with the...
Dupilumab use in atopic dermatitis patients not associated with cancer development Aditi21 April 2023 8:00 PM ISTNewyork: A 5-year retrospective study published in The Journal of Allergy and Clinical Immunology: In Practice concluded that atopic dermatitis...
Dupilumab highly effective in reducing symptoms of eczema in children less than 6 years Dr. Kamal Kant Kohli11 April 2023 9:45 AM IST Dupilumab is a monoclonal antibody that targets a key immune pathway in allergies. According to a new study Researchers at Northwestern Medicine have...
Sanofi Dupixent gets European Commission nod for children aged 6 months to 5 years old with severe atopic dermatitis Ruchika Sharma22 March 2023 12:45 PM ISTDupixent is an injection administered under the skin at different injection sites.
Add on topical steroids to Dupilimab monotherapy fail to further improve outcomes in Atopic dermatitis Jacinthlyn Sylvia15 March 2023 2:45 AM ISTAddition of topical corticosteroids to Dupilimab does not further improve the outcomes in patients with moderate to severe Atopic Dermatitis, finds a...
Dupilumab improves urticaria activity and QoL in patients with chronic spontaneous urticaria Medha Baranwal13 March 2023 8:00 PM ISTUSA: A recent study has found that patients with chronic spontaneous urticaria treated with dupilumab experienced a significant improvement in quality...
Sanofi Dupixent application for treatment of chronic spontaneous urticaria in adults, adolescents accepted for USFDA review Ruchika Sharma7 March 2023 3:30 PM ISTDupixent is a fully human monoclonal antibody that inhibits the signaling of the IL-4 and IL-13 pathways and is not an immunosuppressant.
Dupilumab rapidly improves treatment outcomes in erythrodermic atopic dermatitis Aditi14 Feb 2023 8:00 PM ISTIllinois: An original investigation published in JAMA Dermatology has concluded that Dupilumab improves signs and symptoms of Atopic dermatitis (AD)...
Dupilumab therapy against Atopic dermatitis associated with conjunctivitis Jacinthlyn Sylvia22 Jan 2023 8:00 PM ISTDupilumab had an 86% two-year medication survival rate, however it was ineffective for treating atopic dermatitis (AD) in the head and neck, and 25%...
